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graft. In autologous [1] [2] [3] [4] and allogeneic transplants of peripheral blood stem cells, 5 several studies have correlated the CD34 + cell dose with haematopoietic engraftment or other clinical outcomes. However, in allogeneic BMT, little information has been provided on the relationship between the marrow CD34 + cell dose and transplant outcome. 6, 7 The purpose of the present study was to evaluate, in 50 adult patients with chronic myeloid leukaemia (CML) undergoing unmanipulated HLA-identical sibling BMT, the possible association between the number of CD34 + cells infused and clinical outcomes, namely haematologic recovery, acute and chronic GVHD, transplant-related mortality and overall survival.
Patients and methods

Patients
Between March 1993 and October 1998, in our unit, 69 consecutive patients with CML received an HLA-identical sibling BMT, 50 of whom were included in this study according to the following criteria of inclusion: age between 15 and 56 years and availability of CD34 + cell counts in the graft. Allogeneic BMT was always proposed as a first line therapy in patients less than 45 years old with an HLA-identical sibling donor. Donor and recipient principal characteristics are shown in Table 1 .
Collection and processing of bone marrow
Major ABO incompatibility was observed in five donorrecipient pairs and minor ABO incompatibility in 10 pairs. Bone marrow (BM) was harvested from both posterior iliac crests under general anaesthesia. BM was collected into an anticoagulant medium consisting of RPMI heparin (for BM collected between 1993 and 1995) or ACD (for BM collected between 1995 and 1998). Final harvested BM had a dilution of 1/3 in RPMI heparin and 1/10 in ACD. The BM was concentrated by centrifugation on a COBE-2991 (IBM) at 3000 rounds/min for 5 min. Supernatant and part of the red blood cells were eliminated. Buffy-coat cells were resuspended in human albumin and infused. In the case of BMT = bone marrow transplantation; CML = chronic myelogenous leukaemia; TBI = total body irradiation; Cy = cyclophosphamide; Bu = busulfan; CsA = cyclosporin A; MTX = methotrexate; TNC = total nucleated cells; CFU-GM = colony-forming unit granulocyte-macrophage.
major ABO incompatibility, red blood cells and plasma were separated from the graft before transplantation. CD34 + cell counts were performed on the buffy coat by flow cytometry. For CD34 analysis, a dual-platform was used. Briefly, one million BM cells at the initial and final steps of the procedure were suspended in phosphate-buffered-saline (PBS) and incubated for 10 min at room temperature with 20 l of HPCA2-PE and anti-CD45-FITC monoclonal antibodies (Becton Dickinson, Le Pont de Claix, France 
Preparative regimen, GVHD prophylaxis and supportive care
Thirty-eight patients (76%) were conditioned with cyclophosphamide (CY) at a total dose of 120-200 mg/kg and busulfan (BU) at a total dose of 16 mg/kg. Twelve patients with more advanced disease received CY + BU associated with VP16 or other drugs (n = 9) and substitution of BU by total body irradiation (n = 3). GVHD prophylaxis consisted of cyclosporin A (CsA) and methotrexate (MTX) in 47 patients and of CsA and steroids in three patients. CsA was administered at 3 mg/kg/day by continuous infusion from day −1 and converted to an oral dose when the patient was able to eat. Oral administration was continued for a minimum of 6 months after BMT. MTX was administered on day +1 (15 mg/m 2 ) and days +3, +6 and +11 (10 mg/m 2 each) in 10 cases, on days +1, +3 and +6 in 31 cases, on days +1 and +3 in four cases and on day +1 in one case. Prophylactic polyvalent immune globulins were administered from the 7th day before BMT to day 100 post transplant. Patients received prophylaxis against HSV with i.v. acyclovir (ACV). ACV was transiently stopped in cases of gancyclovir (GCV) or foscarnet (PFA) treatment of CMV infection or disease. Administration of fluconazole and sulfametoxazole/trimethoprim was used as prophylaxis for fungal and Pneumocystis carinii infection, respectively. All patients were isolated in laminar flow rooms. During the last 5 years no significant change in supportive care was made.
Study endpoints and definitions
Neutrophil recovery was defined as the first of 3 consecutive days when the absolute number of neutrophils was у0.5 ϫ 10 9 /l and у1.0 ϫ 10 9 /l. Platelet engraftment was defined as the time to reach a sustained platelet count у20 ϫ 10 9 /l in the absence of platelet transfusions for 7 consecutive days and a platelet count у50 ϫ 10 9 /l without transfusion. All patients were considered at risk starting on day 1 for the occurrence of acute GVHD, whereas only those surviving for more than 100 days after transplant and had sustained engraftment were evaluated for the development of chronic GVHD. Acute and chronic GVHD were defined according to established criteria. 8, 9 Overall survival was the time between transplantation and death due to any cause. Transplant related mortality (TRM) at day 100 was defined as all causes of non-leukaemic deaths at day 100 after transplant.
Statistical analysis
All patients had a last follow-up time on 1st May 1999. The method of Kaplan and Meier was used for estimating the probability of the following clinical events: engraftment at day 40, acute and chronic GVHD (at day 100 and at 2 years, respectively), overall survival at 2 years and TRM at day 100. The following variables were considered for univariable predictive analysis: donor age (Ͻ39 years vs у39 years), recipient age (Ͻ40 years vs у40 years), donor and recipient sex (male vs female), CMV serology (positive vs negative), time interval between diagnosis and transplan- /kg). Cut-offs of age (donor and recipient), time interval between diagnosis and BMT, number of nucleated cells, CFU-GM and CD34 cells infused were chosen based on median values. Associations of these factors with every clinical event were analysed using log-rank tests and proportional hazards regression modelling. The median value of 3.12 ϫ 10 6 CD34 + cells infused was selected for further analysis. Differences in patient's disease and transplant-related factors were analysed according to whether they had received more (n = 25) or less (n = 25) than 3.12 ϫ 10 6 CD34/kg. Using an exact Fisher test for categorical variables and the KruskalWallis test for continuous variables, comparisons of the distribution of variables between the two groups were performed. A multivariate analysis based on the Cox model was used for survival with variables selected as having P Ͻ 0.05, by the log rank test. All P values were two-sided, with P values of 0.05 or less indicating statistical significance. Statistical analyses used the SAS (SAS, Cary, NC, USA) software package.
Results
Median follow-up was 38 months (range 6-67 months). According to Gratwohl et al, risk for patients with CML before transplant, 10 41 (82%) had a score below 3. There was no difference in pretransplant characteristics between patients receiving more or less than 3.12 ϫ 10 6 CD34/kg (Table 2) .
Haematopoietic recovery
The Kaplan-Meier estimate for neutrophils recovery on day 30 was 100% with a median time to reach 0.5 ϫ 10 9 /l neutrophils of 19 days (range 12-24 days). In univariate analysis, the number of CD34 + cells infused/kg did not influence the speed of neutrophil recovery (hazard rate (HR) = 0.90, 95% confidence interval (95 CI): 0.79-1.04; P = 0.17). The only factor significantly associated with neutrophil engraftment was the gender of the patient: the median time to neutrophil engraftment was 18 days in female patients compared to 21 days in male patients (P = 0.003). The actuarial probability of platelet recovery on day 180 was 90% with a median time to reach у20 ϫ 10 9 /l platelets of 34 days (range 14-166 days). No correlation was found between the number of CD34
+ cells infused/kg and the speed of platelet recovery (P = 0.12). We also analysed neutrophil recovery (у0.5 and у1.0) at days 21, 30 and 45 and platelet recovery (у20 ϫ 10 9 /l and у50 ϫ 10 9 /l) at days 30, 60, 90 and 180 after BMT in patients receiving more and less than 3.12 ϫ 10 6 /kg CD34 + cells and no correlation was found between the number of CD34 + cells infused/kg and early or late myeloid recoveries (data not shown).
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Acute and chronic GVHD
The Kaplan-Meier estimate of acute GVHD (уII) at day 100 was 53 ± 14% Fifteen patients had grade II, 10 grade III and one patient grade IV. The number of CD34 + cells infused did not affect the risk of acute GVHD (P = 0.92). In univariate analysis, the actuarial risk of grade II to IV GVHD was significantly higher in patients transplanted in an advanced phase of CML compared to those transplanted in first chronic phase (83 vs 43%, P = 0.005). Chronic GVHD occurred in 21 of 39 patients at risk. It was limited in 10 cases and extensive in 11 cases. The Kaplan-Meier estimate of chronic GVHD rate at 2 years was 46 ± 19%. The number of nucleated cells infused у2 ϫ 10 8 /kg and CD34 + cells у3.12 ϫ 10 6 /kg decreased the probability of chronic GVHD, (P = 0.01 and P = 0.04, respectively).
Overall survival
Twenty-five patients were alive at last follow-up. The actuarial probability of 2-year survival was 46 ± 15%. In univariate analysis, the CD34 + cell dose was the only factor affecting survival: a significantly higher survival was observed in the group receiving more than 3.12 ϫ 10 6 CD34/kg (72 vs 20%, P = 0.0006) (Figure 1 ). The number of TNC infused higher than the median of 2.18 ϫ 10 8 /kg was also associated with a significantly higher 2-year overall survival (60 vs 29%, P = 0.03). In a multivariate analysis, factors associated with increasing risk of death were advanced disease status at transplant (HR: 2.5 (95% CI: 1.09-5.75), P = 0.03) and number of CD34 + cells infused/kg below the median (HR: 4.55 (95% CI: 1.87-10.90), P = 0.0008).
Transplant-related mortality (TRM), causes of death and relapses
Causes of death are summarised in Table 3 . The main causes of death were represented by transplant-related complications. Eleven of 23 transplant-related deaths occurred before day 100 after transplantation. Day 100 TRM was estimated at 22 ± 12%. In univariate analysis, the risk of TRM was significantly higher in the group receiving less than 3.12 ϫ 10 6 CD34/kg (36 vs 7%, P = 0.009) and in patients older than 40 years (36 vs 5%, P = 0.009). Otherwise, a non-significant trend of a higher probability of TRM was observed in patients with an interval between diagnosis and BMT of more than 1 year (33 vs 12%, P = 0.06).
Mortality due to infections, especially fungal, was significantly higher in patients receiving less than 3.12 ϫ 10 6 CD34/kg compared to those receiving more than 3.12 ϫ 10 6 CD34/kg (48 vs 16%, P = 0.01). However, the incidence of infections in the first 3 months after transplant in both sets of patients was comparable. Finally, the incidence of other transplant-related complications (acute GVHD, liver veno-occlusive disease, haemorrhagic cystitis, acute respiratory distress syndrome) was comparable in both groups but severity was increased in the group of patients receiving the lowest dose of cells.
Only seven patients relapsed (three molecular and four cytogenetic relapse). The Kaplan-Meier estimate of relapse at 5 years was 28%.
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Discussion
The importance of the CD34 + cell dose for haematopoietic reconstitution after transplantation was first demonstrated in autologous [1] [2] [3] [4] and more recently in allogeneic peripheral blood stem cell transplants. 5 In allogeneic BMT, few studies addressed the relationship between numbers of haematopoietic progenitors (CFU-GM) 11, 12 or CD34 + cells infused. 6, 7 and the clinical outcome after transplantation. However, the importance of the marrow cell dose has been emphasized in unrelated donor BMT in patients with high risk acute leukaemia. In a series of 174 patients with acute Table 3 Causes of death according to CD34 + cell dose infused to recipient leukaemia, a marrow cell dose above the median value of 3 ϫ 10 8 /kg nucleated cells was associated with faster neutrophil and platelet engraftment and decreased severe acute GVHD. In patients transplanted in remission, a marrow cell dose above the median resulted in less non-leukaemic deaths and better leukaemia-free survival. Transplant in remission with a high dose of marrow cells was associated with the best outcome in both children and adults. 13 It has been shown previously that counting marrow CD34 + cells gave a better estimate of haematopoietic stem cell content compared to measuring the total number of nucleated cells.
14 In order to minimise heterogeneity due to 11, 15 and also to our own internal controls where we found a median dose of 3.9 ϫ 10 6 CD34 + cells/kg (0.10-26) in 329 consecutive patients. Inter-laboratory variability in quantification of CD34 + cells makes comparison of data generated by different laboratories difficult because of technical variations in CD34 + cell counting. 16, 17 In the present study, we did not find any correlation between the number of marrow CD34 + cells infused and the time to neutrophil or platelet engraftment. We found a correlation between the number of total nucleated cells (TNC) and the number of CD34 + cells infused. This translated to the same results concerning engraftment and survival; there was no correlation between the number of TNC infused and time to neutrophil recovery (P = 0.44) while a number of TNC infused higher than the median of 2.18 ϫ 10 8 /kg was associated with a significantly higher 2-year overall survival (60 vs 28%, P = 0.03) and tended to be associated with a decreasing risk of TRM (13 vs 35%, P = 0.06). A positive correlation between the number of CFU-GM infused and the speed of neutrophil recovery was suggested by some studies, 3, 18 but not by others. 12 However, here also the interpretation of the results is difficult because of technical differences between centres. In a study on T cell-depleted marrow transplants, 7 the number of CD34 + cells infused had no effect on the speed of neutrophil engraftment. The optimum CD34 + cell dose required for fast haematopoietic engraftment in allogeneic BMT has been estimated at 3 ϫ 10 6 marrow CD34 + cells/kg. The speed of engraftment might be influenced by factors other than total number of marrow CD34 + cells. It is well known that CD34
+ cells represent a heterogeneous population consisting of different subsets with different roles in haematopoietic reconstitution. Among other properties, the proliferative potential of haematopoietic stem cells (CD34 + CD38 + ) decreases with the age of donor by loss of telomeric DNA with age. 19 On the other hand, immunological factors comprising lymphocyte subsets affect engraftment independently of the number of CD34 + cells infused. 20, 21 This could explain the difficulty in detecting the effect of the CD34 + cell dose on time to engraftment in unmanipulated transplants. We have also looked at the influence of CD34 cell dose on late neutrophil and platelet recovery and we failed to detect any influence on late haematopoietic reconstitution.
Previous studies, in T cell-depleted BMT, showed a significant influence on survival and risk of TRM of the number of CFU-GM 12 or CD34 + cells. 6, 7 In these studies, a higher number of haematopoietic progenitors had a favourable effect on survival by improving TRM and decreasing the relapse rate. Higher risk of TRM in patients receiving lower dose of progenitors appeared to be associated with an increased incidence of infections. 7, 12 In our study, the number of CD34 + cells infused was not associated with a higher number of infections but with death due to infection which was significantly higher in patients receiving less
Bone Marrow Transplantation than 3.12 ϫ 10 6 CD34/kg (48 vs 16%, P = 0.01). This finding might suggest that an earlier recovery of the myelomonocyte compartment is observed with a higher CD34 + cell dose. 7 Recently, Storek et al, 22 described that low B cell and monocyte counts on day 80 were associated with high infection rates between days 100 and 365 after allogeneic marrow transplantation. We can speculate that the CD34 + cell dose has a role on immune reconstitution including lymphocyte and monocyte recovery that could explain the reason for the impaired immune function in those patients receiving a low CD34 + cell dose. We are currently studying the impact of the CD34 + cell dose on haematopoietic subsets in a larger series of patients.
The relationship of the CD34 + cell dose with GVHD has been studied in several randomised studies comparing allogeneic BMT and PBSCT. In our study as well as others, we did not show any correlation between the number of bone marrow CD34
+ cells infused and an increased risk of acute GVHD. [23] [24] [25] We found an inverse correlation of TNC and CD34
+ cell dose and the probability of chronic GVHD as described by others. 13, 21 In our study, the number of CD34 + cells Ͻ3.12 ϫ 10 6 /kg was associated with a higher risk of chronic GVHD (P = 0.04).
In conclusion, our results show that the marrow CD34
+ cell dose had a dramatic influence on survival in adults receiving an HLA-identical sibling BMT for CML. The mechanism of this effect is not obvious, as we did not find that the cell dose modified the speed of engraftment. However, it modified the severity of infections suggesting that the effect is probably related to qualitative differences in different cell subsets. These results are of importance as they emphasise the necessity of quantifying the transplant not only by measuring the number of nucleated cells but also by using flow cytometry analyses for measurement of haematopoietic progenitors and lymphoid subsets.
